Publications
Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.
Journal: Clinical Pharmacology in Drug Development
Authors: Tyler T, Schultz A, Venturini A, Giuliano C, Bernareggi A, Spezia R, Voisin D, Stella V
Paradigmenwechsel in der Glukosekontrolle: Urin-, Blut-, interstitielle Glukosemessung.
Journal: Diabetologie und Stoffwechsel
Authors: Forst T
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
Journal: Scientific Reports
Authors: Fontes MSC, Dingemanse J, Halabi A, Tomaszewska-Kiecana M, Sidharta PN
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.
Journal: ERJ Open Research
Authors: Maher TM, Schlecker C, Luedtke D, Bossert S, Zoz DF, Schultz A.
First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.
Journal: British Journal of Clinical Pharmacology
Authors: Klein S, Gashaw I, Baumann S, Chang X, Hummel T, Thuß U, Friedrich C
New strategies to improve clinical outcomes for diabetic kidney disease.
Journal: BMC Medicine
Authors: Forst T, Mathieu C, Giorgino F, Wheeler DC, Papanas N, Schmieder RE, Halabi A, Schnell O, Streckebein M, Tuttle KR
Diabetes Mellitus and the Heart.
Journal: Experimental and Clinical Endocrinology & Diabetes
Authors: Schütt K, Forst T, Birkenfeld AL, Zirlik A, Müller-Wieland D, Marx N
Influence of hepatic impairment on the pharmacokineticsand pharmacodynamics of the P2Y12 receptor antagonist selatogrel
Journal: Clinical and Translational Science
Authors: Schilling U, Hsin CH, Delahaye S, Krause A, Wuelfrath H, Halabi A, Dingemanse J.
100 Jahre Insuline Vergangenheit – Gegenwart – Zukunft / Insuline: Was können sie – worauf hoffen wir?
Journal: diabetes-online
Authors: Forst T.
Pharmacokinetics, pharmacodynamics, and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
Journal: British Journal of Clinical Pharmacology
Authors: Kubitza D, Heckmann M, Distler J, Koechel A, Schwers S, Kanefendt F.
Understanding Biosimilar Insulins – Development, Manufacturing, and Clinical Trials
Journal: Journal of Diabetes Science and Technology
Authors: Heinemann L, Davies M, Home P, Forst T, Vilsbøll T, Schnell O.
First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
Journal: Journal of Thrombosis and Haemostasis
Authors: Nowotny B, Thomas D, Schwers S, Wiegmann S, Prange W, Yassen A, Boxnick S
Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects.
Journal: Frontiers in Pharmacology
Authors: Hoerr R, Zimmermann A, Seitz F, Dienel A
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
Journal: Cardiovascular Diabetology
Authors: Oliver Schnell, Tadej Battelino, Richard Bergenstal, Matthias Blüher, Michael Böhm, Frank Brosius, Richard D. Carr, Antonio Ceriello, Thomas Forst, Francesco Giorgino, Bruno Guerci, Hiddo J. L. Heerspink, Baruch Itzhak, Linong Ji, Mikhail Kosiborod, Nebojša Lalić, Michael Lehrke, Nikolaus Marx, Michael Nauck, Helena W. Rodbard, Giuseppe M. C. Rosano, Peter Rossing, Lars Rydén, Francesca Santilli, Petra‑Maria Schumm‑Draeger, Per Olav Vandvik, Tina Vilsbøll, Christoph Wanner, Carol Wysham, Eberhard Standl
Pharmacokinetics, Safety, and Tolerability of the α2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects.
Journal: Clinical Pharmacology in Drug Development
Authors: Kapsa S, Thuss U, Boxnick S, Schaumann F, Schultz A, Unger S, Otto C